From Alchemy to IPO: The Business of Biotechnology

• ISBN13: 9780738204826
• Condition: NEW
• Notes: Brand New from Publisher. No Remainder Mark.

Product Description
A fascinating glimpse inside the life-and-death business of biotechnology.

“A tour-de-force for anyone who is interested in the biotech industry. I applaud the enormous achievement of Cynthia Robbins-Roth.” -Frederick Frank, Senior Managing Director & Vice Chair, Lehman Brothers

“From Alchemy to IPO tells the dramatic story of this revolutionary industry as only an insider can.” -George Rathmann, President and CEO, ICOS Corporation, Chairman Emeritus, Amgen

Written by a well-known industry insider, From Alchemy to IPO addresses the coming-of-age of biotech products and companies and traces the history of biotechnology from its early inception in the seventies to today’s heyday of new solutions and breakthrough treatments. It describes the amazing entrepreneurial trail of product development, novel business models, and critical trials that eventually pave the way to market. This is the first book to accurately record the inner workings of an industry-biotechnology-that’s on the verge of living up to its monumental promise to change the world as we know it.Amazon.com Review
Despite unnerving swings in individual stock valuations–or perhaps because of them–many knowledgeable observers still believe the 21st century will ultimately earn its stripes as the Age of Biotech. Cynthia Robbins-Roth, named by Forbes magazine as one of the industry’s top insiders, certainly is among them. And in From Alchemy to IPO, she persuasively argues investors better take heed because they ain’t seen nothin’ yet. “Most of us think of biotech as medicine or genetically engineered crops,” writes Robbins-Roth. But in the very near future, she continues, it also “may make it possible for humans to reach the stars and to change the environment on other planets.” Think that’s far-fetched? She says developments like this are already in early stages and, in a deliberately proselytizing manner, traces their roots to the current business nitty-gritty, finally focusing on the long-term moneymaking potential. “The biotech world will never be an easy place for investors,” she cautions, but with hundreds of ongoing projects “poised to power into the marketplace,” there will be plenty of “opportunities for investors and employees alike.” Recommended for readers seeking an informed tutorial on this field of the future. –Howard Rothman

Buy from AMAZON From Alchemy to IPO: The Business of Biotechnology

Science Lessons: What the Business of Biotech Taught Me About Management

• ISBN13: 9781591398615
• Condition: NEW
• Notes: Brand New from Publisher. No Remainder Mark.

Product Description
Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America’s best companies to work for.

In Science Lessons, Gordon Binder–CEO and chairman during 1988-2000–describes Amgen’s climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.

Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges–such as managing creative employees, navigating the IPO process, and protecting intellectual property.

This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great–offering valuable lessons for all companies.

Buy from AMAZON Science Lessons: What the Business of Biotech Taught Me About Management

How To Identify Mutual Funds To Invest In

When looking for a place to invest in, we are always looking for that investment that will give us the best returns, the best services and the lowest risk. Many people are now opting for mutual funds because they tend to meet these qualifications. While this is on a more general note, the wisdom lies in being able to know the type of mutual funds that specifically meets these conditions. There are many types of bonds, holdings and securities that are to be found under this type of investment.

The best type of investment is the one that presents you with the chance to diversify your chances of getting good returns. The investments that are in the current market and which can provide you with diversity include biotech mutual funds. which include companies like Amgen (NASDAQ:AMGN), Genentech (NYSE:DNA) Gilead Sciences (NASDAQ:GILD), Rydex’s Biotechnology Inv, and Quaker’s Biotech Pharma-Healthcare.

Biotech investments are better priced than most others and they are commonly invested in by large corporations. The secret to getting the best investment is to buy those that are associated with large companies as compared to those owned by small trying companies. However, that is not all. Getting the big picture on their ratings will also go a long way in helping you determine how good they are. If they are charging high fees in the hard economic times, then they are probably the type of investments to keep away from.

Other investments that you may find in the market and which can be considered to be relatively favourable are in the domestic, bond, international, index and other sectors categories. The largest company that trades in them does a lot of research to ensure that they keep up with the current happenings in the world of investment. Their services have also got a four or five star rating from the Morning Star Newspaper.

Background Requirements For A Career In Biotechnology

If you’re seeking a career in biotechnology, one thing is for certain … the more education you have, the higher up you can go. The fact is, no matter where you wind up working, you will be surrounded by people with Ph.D.’s and medical degrees. It is highly unlikely that an individual without an advanced degree such as these will get to the top of the corporate chain.

Therefore a bachelor’s degree in the life sciences is a bare minimum. After that, it is recommended that you pursue an advanced degree; whether it be a master’s degree or higher. Common degrees include; molecular biology, cell physiology, biochemistry, genetics and the like.

You should plan to take as many labs in college as possible as these will provide you with hands-on experience. Teaching as a student-teacher is also a wise move, as is becoming a part of a research project. It is possible to co-author a quality research paper before you ever even graduate with a bachelor’s degree.

Biotechnologists frequently gain employment for biotech corporations. Over the last two decades, thousands of biotech corporations have sprung up around the globe. From start-ups to companies the size of Amgen, the choices range from pay to research to prestige.

Employment in the biotech industry may also be sought in academic institutes; such as universities and non-profit organizations. These typically pay less than biotech corporations, but may have more opportunities for independent research.

As a biotechnologist, you will spend most of your work hours in a laboratory. The work can be tedious and requires patience, but many truly enjoy working with their hands. You will design and carry out experiments and will need to keep good records.

The best biotechnologists enjoy innovation and the spirit of helping to advance society. If you choose biotechnology as a career, you can expect to be right on the cutting edge of technology.